The Discounted Cash Flow (DCF) valuation of Intra-Cellular Therapies Inc (ITCI) is (456.60) USD. With the latest stock price at 131.87 USD, the upside of Intra-Cellular Therapies Inc based on DCF is -446.3%.
Based on the latest price of 131.87 USD and our DCF valuation, Intra-Cellular Therapies Inc (ITCI) is a sell. selling ITCI stocks now will result in a potential gain of 446.3%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 4.9% - 7.6% | 6.3% |
| Long-term Growth Rate | 3.0% - 4.7% | 3.8% |
| Fair Price | (4,487.19) - (239.57) | (456.60) |
| Upside | -3502.7% - -281.7% | -446.3% |